ArticleTherapeutic advances in medical oncology2026
Lorlatinib-specific outcomes by timing of lorlatinib initiation in advanced ALK-positive non-small cell lung cancer: A retrospective cohort study.
Ruiqi Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.